Search and analyze individual stocks with comprehensive metrics

AngloGold Ashanti plc

ANGPharmaceuticals
23.95+0.00 (+0.00%)
As on 19 Jan 2026, 10:10 amMarket Closed

Fundamental Score

...

AngloGold Ashanti plc Share Price Live NSE/BSE

No data
High
0.00
Low
0.00
Volume
0
Change
+0.00%

Profitability Metrics

Poor

Return on Equity

-17.05%
Poor

Return on Capital Employed

-4.18%
Average

Operating Profit Margin (5Y)

10.94%
Poor

Dividend Yield

0.00%

Valuation Metrics

Price to Earnings

N/A

Market Capitalization

38.36 (Cr)

Industry P/E

31.77x

Growth Metrics

Poor

YoY Quarterly Profit Growth

-41.15%
Poor

YoY Quarterly Sales Growth

-20.77%

Sales Growth (5Y)

N/A

EPS Growth (5Y)

N/A

Profit Growth (5Y)

N/A

Financial Health

Poor

Debt to Equity

1.52x
Poor

Interest Coverage

-0.96x

Free Cash Flow (5Y)

N/A

Ownership Structure

Good

Promoter Holding

70.60%
Poor

FII Holding

0.00%
Poor

DII Holding

0.00%
Poor

Pledged Percentage

44.88%
Market-cap Classification
Small-cap
Higher growth potential with higher volatility.
70.60%
Promoter Holding
38.36 (Cr)
Market Cap

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Market Data Analysis & Educational Insights

Educational evaluation of ANG across key market metrics for learning purposes.

Positive Indicators

1 factors identified

Balanced Promoter Holding (70.60%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.

Risk Factors

11 factors identified

Below-Average Return on Equity (-17.05%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (-4.18%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.

Profit Decline Concern (-41.15%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.

Revenue Contraction (-20.77%)

Observation: Sales decline may indicate market challenges or competitive pressures.

Analysis: Negative revenue growth requires analysis of market conditions and competitive positioning. Monitor recovery strategies.

Elevated Debt Levels (D/E: 1.52)

Observation: High leverage increases financial risk and interest burden.

Analysis: High debt-to-equity ratios require monitoring of debt servicing capability and cash flow generation.

Weak Interest Coverage (-0.96x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability. Monitor cash flow and debt reduction plans.

High Share Pledging Risk (44.88%)

Observation: Significant promoter share pledging creates potential overhang.

Analysis: High pledging levels may create selling pressure during market downturns or margin calls.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.

High Debt-to-Equity Ratio

Observation: Elevated financial risk due to high leverage.

Analysis: High debt levels may strain cash flows and increase financial risk during economic downturns.

Very Low ROE

Observation: Poor capital utilization and shareholder returns.

Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.

Small Market Cap

Observation: Higher investment risk due to limited size.

Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.

Loading Peer Comparison

Finding companies in the Pharmaceuticals sector...

Financial Statements

Comprehensive financial data for AngloGold Ashanti plc

About ANG

Business Overview

ANG Lifesciences India Limited engages in manufacturing and sale of finished pharmaceutical formulations in India and internationally. Its product portfolio comprises therapeutics categories, such as antibiotics, antiviral, antimalarial, antiulcer, carbapenem, corticosteroid, penicillin, and beta lactamase inhibitor. The company offers its finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials, liquid injection vials, ampoules, PFS, hard gelatin capsules, soft gelatin capsules, dry syrups, liquid syrups and suspension, and lotions. ANG Lifesciences India Limited was incorporated in 2006 and is based in Amritsar, India.

Company Details

Symbol:ANG
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Rajesh Gupta
MD & Executive Director
Ms. Saruchi Gupta
CFO & Whole Time Director
Mr. P.K. Sharma
Deputy General Manager of Human Resources & Administration

ANG Stock Details & Analysis

Key Financial Metrics

Return on Equity (ROE)-17.05%
Return on Capital Employed-4.18%
Operating Profit Margin (5Y)10.94%
Debt to Equity Ratio1.52
Interest Coverage Ratio-0.96

Growth & Valuation

Sales Growth (5Y)N/A%
Profit Growth (5Y)N/A%
EPS Growth (5Y)N/A%
YoY Quarterly Profit Growth-41.15%
YoY Quarterly Sales Growth-20.77%

Frequently Asked Questions

What is the current price of AngloGold Ashanti plc (ANG)?

As of 19 Jan 2026, 10:10 am IST, AngloGold Ashanti plc (ANG) is currently trading at ₹23.95. The stock has a market capitalization of ₹38.36 (Cr).

Is ANG share price Overvalued or Undervalued?

ANG is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Fairly Valued against its sector peers.

What factors affect the AngloGold Ashanti plc share price?

Key factors influencing ANG's price include its quarterly earnings growth (Sales Growth: -20.77%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).

Is AngloGold Ashanti plc a good stock for long-term investment?

AngloGold Ashanti plc shows a 5-year Profit Growth of N/A% and an ROE of -17.05%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 1.52 before investing.

How does AngloGold Ashanti plc compare with its industry peers?

AngloGold Ashanti plc competes with major peers in the Pharmaceuticals. Investors should compare ANG's P/E of 0.00x and ROE of -17.05% against the industry averages to determine its competitive standing.

What is the P/E ratio of ANG and what does it mean?

ANG has a P/E ratio of N/Ax compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹N/A for every ₹1 of annual earnings.

How is ANG performing according to Bull Run's analysis?

ANG has a Bull Run fundamental score of N/A/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.

What sector and industry does ANG belong to?

ANG operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting AngloGold Ashanti plc.

What is Return on Equity (ROE) and why is it important for ANG?

ANG has an ROE of -17.05%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently AngloGold Ashanti plc generates profits from shareholders' equity.

How is ANG's debt-to-equity ratio and what does it indicate?

ANG has a debt-to-equity ratio of 1.52, which indicates high leverage that increases financial risk. A ratio below 1.0 generally indicates conservative financing.

What is ANG's dividend yield and is it a good dividend stock?

ANG offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.

How has ANG grown over the past 5 years?

ANG has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.

What is the promoter holding in ANG and why does it matter?

Promoters hold 70.60% of ANG shares, with 44.88% of promoter shares pledged. High promoter holding often indicates strong management confidence.

What is ANG's market capitalization category?

ANG has a market capitalization of ₹38 crores, placing it in the Small-cap category.

How volatile is ANG stock?

ANG has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.

What is the 52-week high and low for ANG?

ANG has a 52-week high of ₹N/A and low of ₹N/A.

What is ANG's operating profit margin trend?

ANG has a 5-year average Operating Profit Margin (OPM) of 10.94%, indicating the company's operational efficiency.

How is ANG's quarterly performance?

Recent quarterly performance shows YoY Sales Growth of -20.77% and YoY Profit Growth of -41.15%.

What is the institutional holding pattern in ANG?

ANG has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.